Investment analysts at Oppenheimer Holdings Inc. assumed coverage on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a research note issued on Monday. The firm set a “buy” rating and a $27.00 price target on the biotechnology company’s stock. Oppenheimer Holdings Inc.’s price target indicates a potential upside of 75.61% from the company’s previous close.

HRTX has been the subject of a number of other research reports. Cantor Fitzgerald set a $31.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a research report on Friday, October 20th. Mizuho began coverage on shares of Heron Therapeutics in a research report on Tuesday, September 26th. They issued a “buy” rating and a $28.00 price objective for the company. BidaskClub upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Jefferies Group LLC restated a “buy” rating and issued a $26.00 price objective on shares of Heron Therapeutics in a research report on Friday, July 14th. Finally, Cowen and Company set a $40.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the stock. Heron Therapeutics presently has a consensus rating of “Buy” and an average target price of $28.36.

Shares of Heron Therapeutics (NASDAQ:HRTX) traded up 1.821% on Monday, hitting $15.375. The stock had a trading volume of 482,333 shares. Heron Therapeutics has a one year low of $12.21 and a one year high of $20.85. The company’s market capitalization is $832.37 million. The firm has a 50 day moving average price of $15.64 and a 200 day moving average price of $15.24.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million during the quarter, compared to the consensus estimate of $4.53 million. On average, equities research analysts predict that Heron Therapeutics will post ($3.50) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Heron Therapeutics, Inc. (HRTX) Earns Buy Rating from Analysts at Oppenheimer Holdings Inc.” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/30/heron-therapeutics-inc-hrtx-earns-buy-rating-from-analysts-at-oppenheimer-holdings-inc.html.

Hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN increased its holdings in Heron Therapeutics by 78.8% during the 1st quarter. Wells Fargo & Company MN now owns 39,579 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 17,442 shares in the last quarter. Janus Henderson Group PLC bought a new position in Heron Therapeutics during the 2nd quarter worth about $78,134,000. Bank of New York Mellon Corp increased its holdings in Heron Therapeutics by 7.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock worth $2,837,000 after purchasing an additional 14,086 shares in the last quarter. Virtu KCG Holdings LLC increased its holdings in Heron Therapeutics by 62.5% during the 2nd quarter. Virtu KCG Holdings LLC now owns 25,053 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 9,637 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Heron Therapeutics during the 1st quarter worth about $2,002,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.